Clinical trials: Brain Metastases From Solid Tumors
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00837928
- Testing
- bendamustine, laboratory biomarker analysis, Surgical Resection of Brain Metastases
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- John Grecula
Solid Tumor Malignancies, Brain Metastases From Solid Tumors
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
- Trial name
- NCT06136884
- Testing
- AO-252
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- A2A Pharmaceuticals Inc.
Brain Metastases
Tumor Bed Hypofractionated IMRT After Surgery for Patients With Single,Large Brain Metastases From Solid Tumor
Investigators designed a study of a multimodality approach: surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach for patients with single, large brain metastases from solid primary…
- Trial name
- NCT02576522
- Testing
- brain metastatic patients
- Where
- Italy
- Volunteers
- 87 people
- Sponsor
- Istituto Clinico Humanitas
Brain Cancer, Neoplasm Metastases
Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)
Cancer patients with brain metastases (BM) have poor prognosis. Current treatments produce limited efficacy. Recent advance in cancer immunotherapy has provided important new means to treat cancer patients at advanced stages.
- Trial name
- PerCellVac3 (NCT02808416)
- Testing
- Personalized cellular vaccine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Guangdong 999 Brain Hospital
Brain and Central Nervous System Tumors, Cognitive/Functional Effects
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children
- Trial name
- NCT00389584
- Testing
- irinotecan hydrochloride, cognitive assessment, management of therapy complications
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Davis
Brain Metastases From Solid Tumors
Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases:
This study is a multicenter, open label, randomized controlled, adaptive phase II/III seamless design clinical trial aimed at comparing the efficacy and safety of methylprednisolone (MP) and dexamethasone (DEX) in the treatment…
- Trial name
- NCT07542288
- Testing
- Methylprednisolone (Corticosteroid), Dexamethasone
- Where
- China
- Volunteers
- 400 people
- Sponsor
- The Second Affiliated Hospital of Hainan Medical University
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
This randomized phase I/II trial studies the side effects and the best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with whole-brain radiation therapy or stereotactic…
- Conditions
- Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01217411
- Testing
- Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Intracranial Metastatic Disease From Any Solid Malignancy
Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy Device
Hippocampal-avoidance whole brain radiation therapy (HA-WBRT) limits radiation dose to the hippocampal-avoidance region while still delivering therapeutic doses of radiation to the whole brain.
- Trial name
- NCT05096286
- Testing
- Ethos Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Recurrent Brain Metastases, Progressive Brain Metastases
Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
Cancer that has spread to the brain, or brain metastasis, is difficult to treat. Meclofenamate is a drug which has been shown to reduce brain metastasis growth in the laboratory.
- Trial name
- NCT02429570
- Testing
- Meclofenamate
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma Multiforme, Brain Neoplasms
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
This is a First-In-Human (FIH) study of [68Ga]-FF58 to characterize the imaging properties, safety, biodistribution and dosimetry properties of [68Ga]-FF58 in adults with relapsed or refractory (r/r) glioblastoma multiforme…
- Conditions
- Glioblastoma Multiforme, Brain Neoplasms, Gastroesophageal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT04712721
- Testing
- 68Ga-FF58
- Where
- 2 sites in France, Germany
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Leptomeningeal Metastases
Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases
The purpose of this study is to find the safest and most effective dose for delivering proton beam to the space containing CSF, brain, and spinal cord, in treating leptomeningeal metastases.
- Trial name
- NCT03520504
- Testing
- Proton craniospinal irradiation (CSI)
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Tumor Adult, Brain Metastases From Solid Tumors
Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer
This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors.
- Conditions
- Brain Tumor Adult, Brain Metastases From Solid Tumors, Brain Tumor, Primary, Brain Tumor
- Trial name
- NCT07226466
- Testing
- Blood sample, Brain magnetic resonance imaging (MRI), Brain Health Assessment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
The goal of this phase II clinical trial] is to analyze the efficacy of patritumab deruxtecan (HER3-DXd) in patients with metastatic breast cancer (MBC) or advanced non-small cell lung cancer (aNSCLC) with active brain metastases…
- Conditions
- Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult
- Trial name
- TUXEDO-3 (NCT05865990)
- Testing
- Patritumab deruxtecan
- Where
- 8 sites in Austria, Spain
- Volunteers
- 63 people
- Sponsor
- MedSIR
Brain Metastases From Solid Tumors
SMART Trial: Cognitive Sparing Brain Radiotherapy for Multiple Brain Metastases
The goal of this phase II randomized trial is to determine if Stereotactic Radiosurgery (SRS) or Cognitive Sparing WBRT (CS-WBRT) better preserves neurocognitive function than standard Hippocampal Avoidance WBRT (HA-WBRT) in…
- Trial name
- NCT07505979
- Testing
- SRS, CS-WBRT, HA-WBRT
- Volunteers
- 90 people
- Sponsor
- National Taiwan University Hospital
Glioblastoma, Brain Metastases
Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study
An open-label, single institutional phase II trial of losartan in patients with primary and metastatic brain tumors with an individual stepped-wedge, randomized, assessor-blinded, dose-finding design on three indications.
- Trial name
- ImPRESS (NCT03951142)
- Testing
- Losartan
- Where
- Norway
- Volunteers
- 165 people
- Sponsor
- Kyrre Eeg Emblem